.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD12_PioglitazoneAndSitaglipt.PioglitazoneAndSitaglipt .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD12_PioglitazoneAndSitaglipt.PioglitazoneAndSitaglipt| name: | PioglitazoneAndSitagliptin |
| ATC code: | A10BD12 | route: | oral |
| n-compartments | 1 |
Pioglitazone and sitagliptin is a fixed-dose combination of an oral antidiabetic thiazolidinedione (pioglitazone) and a dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin) used in the management of type 2 diabetes mellitus. Pioglitazone increases insulin sensitivity, while sitagliptin enhances incretin hormone levels, leading to improved glycemic control. This combination is approved in several countries for use as part of a comprehensive diabetes treatment regimen.
Estimated composite pharmacokinetic parameters for healthy adult subjects, based on published data for individual drugs (pioglitazone and sitagliptin), as no specific published population pharmacokinetic models for the fixed-dose combination were located.
Kadokura, T, et al., & Smulders, R (2014). Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. Clinical pharmacokinetics 53(11) 975–988. DOI:10.1007/s40262-014-0180-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/25316572
Scheen, AJ (2015). Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75(1) 33–59. DOI:10.1007/s40265-014-0337-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/25488697